Granules India Ltd Share Price

Granules India Limited, a pharmaceutical company founded in 1984, has established itself as a significant player in the industry. Headquartered in Hyderabad, Telangana, the company specialises in manufacturing Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs).

Dr. Krishna Prasad Chigurupati, the Chairman & Managing Director, owns 31.69% shares of the company. Under his leadership, Granules India has grown to become a globally recognized pharmaceutical manufacturer.

Apart from him, there are a few managerial promoters who have contributed to the success of the company. They are
● Harsha Chigurupati
● Kolli Basava Sankar Rao
● Sucharita Rao Palepu
● Arun Sawhney
● Priyanka Chigurupati
The company is known for producing large-scale quantities of common drugs. They include Paracetamol, Ibuprofen, Metformin, and Guaifenesin.

While not the largest in terms of market share or capitalization, Granules India has built a strong reputation. This is based on manufacturing excellence, process innovation, and regulatory expertise. Its reputation has also helped it maintain a competitive edge in the global pharmaceutical landscape.

The company’s registered office is located in Madhapur, Hyderabad, Telangana. Meanwhile, Granules India’s registrars are located in the Financial District. Throughout its history, Granules India has consistently focused on quality and innovation. The company serves the global pharmaceutical market with essential drugs. Its longevity and success in the industry underscore its ability to adapt to changing market conditions.

How Granules India Ensures Drug Safety

Granules India is a prominent pharmaceutical company known for its commitment to drug safety and quality. Ensuring the safety of its products is a multifaceted process that involves stringent quality control measures, regulatory compliance, and continuous improvement. Here is a detailed look at how Granules India ensures drug safety.

Granules India places a strong emphasis on quality control and assurance. The company has established robust quality management systems that adhere to international standards. These systems are made to monitor every stage of the manufacturing process, from raw material procurement to the final product. In this way, Granules ensures that each batch of drugs meets the required safety and efficacy standards.

The company’s quality control laboratories are equipped with advanced analytical instruments. These instruments are used to conduct various tests. They include chemical, physical, and microbiological analyses. This comprehensive testing helps identify potential contaminants or deviations from the specified quality parameters. As a result, Granules minimises the risk of contamination and ensures the production of safe and effective drugs.

Compliance with regulatory requirements is a cornerstone of Granules India’s approach to drug safety. The company operates in multiple international markets, each with its own set of regulatory standards. Granules ensures that its manufacturing facilities and processes comply with the regulations of agencies such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO).

Granules India has a dedicated regulatory affairs team that stays updated with the latest changes. They ensure that the company’s practices are aligned with these requirements. This team is also responsible for submitting the necessary documentation and managing inspections. As a result, Granules demonstrates its commitment to producing safe and high-quality pharmaceutical products.

Granules India is committed to continuous improvement and innovation in its manufacturing processes. The company invests in research and development (R&D) to enhance the safety and efficacy of its products. This allows Granules to explore new technologies and methodologies. As a result, it can improve drug formulation and enhance product quality.

One of the key areas of focus for Granules is the development of novel drug delivery systems. These systems are designed to improve the bioavailability and therapeutic effectiveness of drugs while minimising side effects. Granules aims to provide patients with safer treatment options by leveraging advanced technologies.

Pharmacovigilance is an integral part of Granules India’s drug safety strategy. The company has established a comprehensive pharmacovigilance system. This is to monitor the safety of its products throughout their lifecycle.

Granules India works with healthcare professionals and patients to gather data on the safety of its products. This information is used to identify potential safety concerns. It is also used to take appropriate actions to mitigate risks. Granules ensure that any safety issues are promptly addressed by maintaining a proactive approach to pharmacovigilance.

Transparency and accountability are fundamental principles that guide Granules India’s operations. The company maintains open communication with regulatory authorities, healthcare professionals, and patients. This helps in building trust and credibility, which are essential for ensuring drug safety.

Granules India also implements robust documentation practices. This is to ensure traceability and accountability in its manufacturing processes. Detailed records are maintained for each batch of drugs. This includes information on raw materials, production parameters, and quality control tests. These records are regularly reviewed and audited to ensure compliance with regulatory requirements.

Granules India’s commitment to drug safety is evident in its comprehensive approach. This includes quality control, regulatory compliance, continuous improvement, pharmacovigilance, training, and transparency. By adhering to these principles, the company ensures that its products are safe, effective, and of the highest quality.